Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 4/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28757558 | 0.90 | ALDH1A1 (0.48) | TAAR1IDO1MAOBALDH1A1KIF11 | |
| SCHEMBL4811925 | 0.90 | ALDH1A1 (0.48) | MAOBALDH1A1KIF11 | |
| SCHEMBL3590959 | 0.88 | TAAR1 (0.44) | TAAR1IDO1HIF1AEPAS1AHR | |
| SCHEMBL6767276 | 0.83 | PTGS1 (0.40) | TAAR1IDO1HIF1AEPAS1CYP1A2 | |
| SCHEMBL5323954 | 0.81 | TAAR1 (0.50) | TAAR1IDO1MAOBKDM4EALDH1A1 | |
| SCHEMBL1992348 | 0.77 | PTGS1 (0.46) | CYP1A2AHRPTGS1MAOBFBP1 | |
| SCHEMBL624798 | 0.77 | TAAR1 (0.50) | TAAR1IDO1CYP1A2MAOBKDM4E | |
| SCHEMBL27932513 | 0.77 | SRD5A2 (0.51) | TAAR1IDO1HIF1AEPAS1CYP1A2 | |
| SCHEMBL27769602 | 0.76 | TAAR1 (0.46) | TAAR1IDO1CYP1A2MAOB | |
| SCHEMBL27769718 | 0.76 | KCNH2 (0.48) | TAAR1HIF1AEPAS1AHRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| EP-4103186-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | Salk Institute for Biological Studies (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021163633-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3452441-A1 | ALPHA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | The Research Foundation for The State University of New York (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9944644-B2 | Octahydropyrrolopyrroles their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-17 | — | — | US | disclosed |
| US-9938291-B2 | N-alkyl-2-phenoxyethanamines, their preparation and use | THE TRUSTESS OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-10 | — | — | US | disclosed |
| US-9872919-B2 | Prodrugs for selective anticancer therapy | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-01-23 | — | — | US | disclosed |
| WO-2017201382-A1 | PURINE NUCLEOTIDE DERIVATIVES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017190034-A1 | AZASTEROIDS FOR TREATMENT OF TUBERCULOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20150315197-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150224208-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150183715-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150150834-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | CHEM-MASTER INTERNATIONAL, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150073053-A1 | TREATMENT OF DRUG RESISTANT CANCER | ROCKEFELLER UNIVERSITY (THE) (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150073021-A1 | CHEMICALLY MODIFIED CURCUMINS AS INHIBITORS OF ANTHRAX LETHAL FACTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140121185-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS CONDITIONS, INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER | MEDICON PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20130225529-A1 | PHOSPHO-ESTER DERIVATIVES AND USES THEREOF | MEDICON PHARMACEUTICALS, INC. | 2013-08-29 | — | — | US | disclosed |
| US-20120095051-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | CHEM-MASTER INTERNATIONAL, INC. | 2012-04-19 | — | — | US | disclosed |
| WO-2010132815-A9 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | TAAR1 409/4885IDO1 649/4885HIF1A 4306/4885 |
| US-20150073021-A1 | CHEMICALLY MODIFIED CURCUMINS AS INHIBITORS OF ANTHRAX LETHAL FACTOR | ANTXR2, APAF1, LITAF | TAAR1 3688/4885IDO1 2253/4885HIF1A 579/4885 |
| US-20150315197-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | TAAR1 361/4885IDO1 3913/4885HIF1A 2805/4885 |
| US-20120095051-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | NFKBIA, NFKB1, NFKB2 | TAAR1 3371/4885IDO1 499/4885HIF1A 461/4885 |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | ULK1, ULK2, ULK3 | TAAR1 4486/4885IDO1 2655/4885HIF1A 1470/4885 |
| US-20150224208-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | NR4A3, ORC3, NTSR1 | TAAR1 364/4885IDO1 2204/4885HIF1A 3591/4885 |
| US-20150150834-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | BAZ2B, CEBPZ, BAZ2A | TAAR1 4781/4885IDO1 4520/4885HIF1A 1409/4885 |
| US-20130225529-A1 | PHOSPHO-ESTER DERIVATIVES AND USES THEREOF | PHOSPHO1, PIK3CA, PYGB | TAAR1 4164/4885IDO1 4784/4885HIF1A 477/4885 |
| US-20150073053-A1 | TREATMENT OF DRUG RESISTANT CANCER | ABCC1, TSG101, NTPCR | TAAR1 3895/4885IDO1 3201/4885HIF1A 1560/4885 |
| US-20150183715-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | FABP1, FABP2, FABP7 | TAAR1 1550/4885IDO1 4305/4885HIF1A 3064/4885 |
| US-20140121185-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS CONDITIONS, INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER | PTGES, PTGES2, HSF1 | TAAR1 3548/4885IDO1 3769/4885HIF1A 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.